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Estimation of the epidemiological burden of carotid atherosclerosis can serve as a basis 
for cardiovascular disease prevention and management. This study provides the first 
estimation on the prevalence, number of cases and risk factors for carotid atherosclerosis 
in the general population globally and regionally. 
Methods  
For this systematic review and analysis, we conducted a comprehensive literature search 
in PubMed, Medline, Embase, Global Health and China National Knowledge Infrastructure 
for articles published until May 2019. Population-based studies that quantified 
prevalence of carotid atherosclerosis by means of elevated carotid intima-media 
thickness (cIMT), carotid plaque (CP), and carotid stenosis (CS), in which elevated cIMT 
was defined as a cIMT ≥1·0 mm, CP as a focal cIMT≥1·5 mm encroaching into the lumen 
or at least 0·5 mm or 50% compared to the surrounding cIMT values, and CS as ≥50% 
stenosis. Age- and sex-specific prevalence rates of elevated cIMT, CP and CS were 
estimated. United Nations population data were used to generate the number of people 
affected from 2000 to 2020. Random-effects meta-analyses were performed to assess the 
effects of risk factors for elevated cIMT and CP. Regional numbers of people living with 
elevated cIMT and CP in 2015 were derived using a risk factors-based model. 
Findings 
59 articles were included in the systematic review and analysis. The prevalence of 
elevated cIMT, CP and CS increased consistently with age and was higher in males than in 
females. Overall, the global prevalence of elevated cIMT, CP and CS in people aged 30-79 
years in 2020 was 27·62%, 21·13% and 1·50%, equivalent to 1066·70 million, 815·76 
million and 57·79 million affected people respectively. Smoking, diabetes and 
hypertension were common risk factors for elevated cIMT and CP. In 2015, Western 
Pacific Region had the most cases of elevated cIMT (317·62 million) and CP (240·77 
million), whereas the African Region had the least cases of elevated cIMT (59·08 million) 
and the Eastern Mediterranean Region had the least CP cases (44·59 million). 
Interpretation  
This study highlights a substantial global burden of carotid atherosclerosis. Effective 
strategies are needed for primary prevention and management of carotid atherosclerosis. 
High-quality epidemiological investigations on carotid atherosclerosis are called for to 
better address the global burden of carotid atherosclerosis at finer levels. 
Funding None. 
  
Research in context 
Evidence before this study 
An up-to-date understanding of the burden of carotid atherosclerosis worldwide is 
imperative for developing effective strategies for primary prevention and management 
and informing stakeholders. However, no current estimation on the prevalence of carotid 
atherosclerosis is available at the global level. 
Added value of this study 
Based on 59 articles, we provided the first robust prevalence estimates of carotid 
atherosclerosis in the general population at both the global and regional levels. The 
prevalence of elevated carotid intima-media thickness (cIMT), carotid plaque (CP) and 
carotid stenosis (CS) increased with advanced age and was higher in males than in 
females. In 2020, the prevalence of elevated cIMT, CP and CS in people aged 30-79 years 
was 27·62%, 21·13% and 1·50%, translating to 1066·70 million, 815·76 million and 
57·79 million cases respectively. 
Implications of all the available evidence 
Elevated cIMT and CP are common disorders in the general population. The large 
numbers of people living with CP and CS worldwide represent a considerable public 




Cardiovascular disease (CVD) has become a leading cause of disability and premature 
mortality globally 1-3. According to the Global Burden of Disease Study, CVD affected an 
estimated 422·7 million people and caused 17·9 million deaths worldwide in 2015, 
representing 31% of all global deaths 1, 4. CVDs are not only diseases of high-income 
countries (HIC). In recent years the burden of CVD has grown disproportionally in low- 
and middle-income countries (LMIC), where over 80% of CVD deaths now occur 3, 5. By 
2030, approximately 23·6 million people are predicted to die from CVDs annually 6. The 
huge and still growing burden of CVDs on individuals, families and the health care system 
suggests an urgent need for research on atherosclerotic diseases and implementation of 
preventive measures. 
Atherosclerosis, the main pathological process of most CVDs, may begin early in life and 
remain latent and asymptomatic for long periods before progressing into its advanced 
stages 7, 8. Early detection of atherosclerosis in apparently healthy people has mainly 
focussed on peripheral arteries and carotid arteries 9. Using ultrasonography, carotid 
intima-media thickness (cIMT) can be non-invasively evaluated 10, 11. According to the 
2016 European Guidelines on cardiovascular disease prevention in clinical practice, a 
cIMT of ≥1·0 mm is generally considered to be abnormal 9. The Mannheim Carotid Intima-
Media Thickness Consensus also suggested that advanced stages of atherosclerosis, 
including plaque, stenosis and occlusion, are indicators of cardiovascular risk 10. In 2010, 
de Weerd  and colleagues established the global prevalence of moderate (≥50% stenosis) 
and severe (≥70% stenosis) carotid stenosis (CS) in asymptomatic people, by using 
systematic review, meta-regression and an individual participant data meta-analysis 12, 13. 
An up-to-date understanding of the burden of carotid atherosclerosis worldwide is 
imperative for developing effective strategies for primary prevention and management 
and informing stakeholders. However, no current estimates of the prevalence of carotid 
atherosclerosis are available at the global level. To fill this gap in knowledge, we 
conducted a systematic review of epidemiological studies that reported the prevalence of 
carotid atherosclerosis in the general population and have included studies using 
different measures of disease. We aimed 1) to provide the age- and sex-specific 
prevalence of carotid atherosclerosis; 2) to establish the main risk factors for carotid 
atherosclerosis; 3) to estimate the global number of people living with carotid 
atherosclerosis from 2000 to 2020; 4) to generate the regional number of people affected 
by carotid atherosclerosis in 2015. 
Methods 
Search Strategy and Study Selection  
A comprehensive literature search was independently performed by two investigators 
(ZF and HZ) from inception to 07 May 2019 covering all epidemiological studies that 
reported the prevalence of three carotid atherosclerotic disorders, namely elevated cIMT, 
carotid plaque (CP) and CS in the general population. Four bibliographic databases, 
including PubMed, Medline, Embase and Global Health, were explored using a 
combination of terms related to carotid atherosclerosis and those related to prevalence 
without restrictions on language or publication date (complete details of the search 
strategies are listed in the appendix, p 3). 
In 2018, we conducted a study on the prevalence of carotid atherosclerosis in China 
through a systematic review and meta-analysis (the China Carotid Atherosclerosis Study), 
where epidemiological studies on the prevalence of elevated cIMT and CP in the general 
Chinese population were included14. For the present systematic review, we updated our 
previous search in the China Carotid Atherosclerosis Study using the largest Chinese 
bibliographic source - China National Knowledge Infrastructure (CNKI) until 08 May 2019. 
This updated search for Chinese literature was also restricted to epidemiological studies 
investigating the prevalence of elevated cIMT, CP and CS in the general Chinese 
population. In addition, hand searches of reference lists from the included articles and 
review articles on the topic were also performed to identify additional eligible articles. 
This present systematic review was conducted in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline 15. The 
review protocol was registered online on PROSPERO a prior (CRD42019134709). 
Two investigators (PS and YZ) independently reviewed abstracts and full-text articles 
using prespecified eligibility criteria. We sought articles that reported prevalence data on 
elevated cIMT, CP or CS and potential risk factors in the general population. To be 
included, studies must have bilaterally scanned carotid arteries using ultrasonography 
and defined elevated cIMT, CP or CS in a standardized manner according to the 2016 
European Guidelines on cardiovascular disease prevention in clinical practice guideline, 
the Mannheim Carotid Intima-Media Thickness Consensus and previous studies, where 
elevated cIMT was defined as a cIMT ≥1·0 mm, CP as a focal cIMT≥1·5 mm encroaching 
into the lumen or at least 0·5 mm or 50% compared to the surrounding cIMT values, CS 
as ≥50% stenosis, including occlusion9, 10, 14. We excluded studies that were conducted in 
people who were not representative of the general population (e.g. people with specific 
diseases, individuals free from CVDs [asymptomatic individuals]). If multiple articles 
provided data from the same investigation, we included the one with the largest sample 
size. 
Data Extraction and Quality Assessment 
The following information from the included articles were independently extracted by 
two investigators (PS and YZ) from the included articles: first author, publication year, 
geographic location of investigation, regions of study location (African Region [AFR], 
Region of the Americas [AMR], South-East Asia Region [SEAR], European Region [EUR], 
Eastern Mediterranean Region [EMR] and Western Pacific Region [WPR], as designated 
by the World Health Organization [WHO]; HIC and LMIC, as designated by the World Bank 
[WB]), study design, investigation date, sample size, average age of participants, 
proportion of female participants, diagnostic method, definition of disease (elevated cIMT, 
CP, or CS), number of cases. For articles where potential risk factors were explored using 
multivariable logistic regressions, the definitions of each risk factor and the reported odds 
ratio (OR) were also abstracted. In articles where the year of investigation was not 
specifically presented, we assigned it as five years, the mean time lag between 
investigation and publication based on articles with available data (appendix, pp 4–5), 
before the publication year. 
To assess the quality of included articles, we employed a quality scale based on the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
statement 16. The quality of each article was rated by two independent investigators (PS 
and YZ) on the basis of five modules: sample population, sample size, participation rate, 
outcome assessment, and analytical methods. Each module was assigned a score of 0-2, 
representing low-, moderate-, and high-quality respectively. The overall score represents 
the overall quality (appendix, p 6). 
Any discrepancies at the bibliographic search, literature review and data extraction stages 
were resolved by consensus through discussion. 
Statistical analysis 
In the present study, the prevalence of elevated cIMT, CP and CS was estimated separately.  
1) Epidemiological modelling of the prevalence of elevated cIMT, CP and CS 
Multiple data points (age- and sex-specific prevalence) were generally provided in the 
included articles. To fully utilize the available information, we adopted a multilevel 
mixed-effects meta-regression17, 18. To control the effects of multiple data points from the 
same study and multiple studies from the same country, the study identification and 
country identification were added into the regression model as the random effect (𝑢𝑖) 19. 
Given that: 
prevalence = p = (elevated cIMT /𝐶𝑃/𝐶𝑆 𝑐𝑎𝑠𝑒𝑠) (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠)⁄  
Then, the prevalence was stabilized with the logit link, 
logit(p) = ln(𝑝 [1 − 𝑝]⁄ ) = ln(𝑜𝑑𝑑𝑠) = 𝛼 + 𝛽1 ∗ 𝑥1 + 𝛽2 ∗ 𝑥2 + ⋯ + 𝑢𝑖 
The effects of cluster-level variables 𝑥1 − 𝑥𝑛 , including age, female proportion, setting 
(rural, urban and mixed), income region (HIC and LMIC), investigation period (before 
2000, 2000-2009, 2010 and after) due to availability of relevant information, were first 
assessed by a univariable meta-regression (appendix, pp 7–8). Age and female 
proportion were found to be significantly associated with the prevalence rates of elevated 
cIMT, CP and CS, therefore,  
logit(p) = 𝛼 + 𝛽1 ∗ 𝐴𝑔𝑒 + 𝛽2 ∗ 𝐹𝑒𝑚𝑎𝑙𝑒 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 + 𝑢𝑖 
Then, 
prevalence = p
= 𝑒(𝛼+𝛽1∗𝐴𝑔𝑒+𝛽2∗𝐹𝑒𝑚𝑎𝑙𝑒 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛+𝑢𝑖) (1 + 𝑒(𝛼+𝛽1∗𝐴𝑔𝑒+𝛽2∗𝐹𝑒𝑚𝑎𝑙𝑒 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛+𝑢𝑖))⁄  
The age- and sex-specific prevalence of elevated cIMT, CP and CS was respectively 
estimated based on the above model. 
2) Estimation of the global number of people with elevated cIMT, CP and CS from 2000 to 
2020 
The numbers of people living with elevated cIMT, CP and CS were respectively generated 
by multiplying the estimated age- and sex-specific prevalence rates by the corresponding 
world populations from 2000 to 2020, obtained from the United Nations Population 
Division (UNPD) 20. To derive robust estimation, we restricted prevalence and number of 
cases to the age range 30-79 years, where most informative data points covered.  
3) Meta-analysis of risk factors for elevated cIMT and CP 
A subset of included articles additionally explored potential risk factors for elevated cIMT, 
CP and CS. Only risk factors that had been assessed in at least three investigations using 
multivariable logistic regressions were included for meta-analysis. A random-effects 
(DerSimonian and Laird method) meta-analysis was used to synthesize the effects of risk 
factors 17. Due to data availability, this was only done for elevated cIMT and CP. 
4) Estimation of the regional number of people with elevated cIMT and CP in 2015 
In line with the China Carotid Atherosclerosis Study and our previous studies, three 
common risk factors for elevated cIMT and CP, including current smoking, hypertension 
and diabetes, were selected. to derive the regional number of people living with elevated 
cIMT and CP based on a risk-factor-based model 14, 21. The latest prevalence data of current 
smoking (in 2015), hypertension (in 2015) and diabetes (in 2015) were obtained from 
the WHO report on the global tobacco epidemic and the WHO Global Health Observatory 
data repository26, 2728, 29.  
The study approach is demonstrated in the appendix (p 47). All analyses were performed 
with Stata, version 14.0 (StataCorp) and R, version 3.3.0 (R Foundation for Statistical 
Computing). 
Results 
The study selection process is summarized in Figure 1. Our initial literature search 
identified 8632 citations. After removal of duplicates and apparently irrelevant records, 
515 articles were examined in full text. Finally, 59 articles covering 21 countries (the 
geographical locations are demonstrated in the appendix, p 48) fulfilled the inclusion 
criteria, among which 25 articles reported prevalence data on elevated cIMT, 34 on CP 
and 16 on CS. The characteristics of every study are shown in the appendix (pp 9–26).  
The majority (n=45, 76·3%) of the included articles were published in the last decade 
(2010-2019), and more than half (n=34, 57·6%) were conducted in rural-urban mixed 
settings. Moreover, 21 (35·6%) and 30(50·8%) of the included articles respectively 
provided age- and sex-specific prevalence rates. Almost half of the included articles (n=28, 
47·5%) were conducted in HIC and the others (n=31, 52·5%) were in LMIC. All the 59 
articles had a quality score of six or above. The detailed quality assessments are in the 
appendix (pp 27–28). 
Based on the available data points from the included articles, the sex-specific 
relationships between age and the prevalence of elevated cIMT, CP and CS were 
demonstrated in Figure 2. Generally, the prevalence of elevated cIMT, CP and CS all rose 
with advanced age. The estimated age- and sex-specific prevalence of elevated cIMT, CP 
and CS is listed in Table 1. For elevated cIMT, CP and CS, females consistently had lower 
prevalence rates than males over the whole age span covered by available data points and 
of research interest (30-79 years). In 2020, the prevalence of elevated cIMT in people 
aged 30-79 years was 27·62% (95% CI=16·92-41·29; males: 32·12% [95% CI=20·17-
46·72]; females: 23·18% [95% CI=13·71-35·93]), that of CP was 21·13% (95% CI=13·24-
31·54; males: 25·18% [95% CI=16·13-36·69]; females: 17·12% [95% CI=10·39-26·46]) 
and that of CS was 1·50% (95% CI=1·08-2·10; males; 1·83% [95% CI=1·31-2·57]; females: 
1·17% [95% CI=0·84-1·63]). 
The numbers of people living with elevated cIMT, CP and CS in the years 2000 and 2020 
were generated by applying the population data to the age- and sex-specific prevalence 
rates (Table 2). Due to demographic ageing during 2000-2020, the numbers of people 
with elevated cIMT, CP and CS increased by 57·49%, 58·97% and 59·13% respectively. 
For elevated cIMT, CP and CS, the age group where the increasing rate was the highest (at 
approximately 85%) was 50-59 years. In 2020, the cases of elevated cIMT, CP and CS 
worldwide were 1066·70 million (95%CI=653·30-1594·52), 815·76 million 
(95%CI=511·36-1217·93) and 57·79 million (95%CI=41·52-81·02) respectively. 
We were able to evaluate the effects of seven factors for elevated cIMT, and nine factors 
for CP in a meta-analysis manner (Table 3). Advanced age, male sex, current smoking, 
diabetes, and hypertension were associated with a higher risk of elevated cIMT. For CP, 
the significant risk factors included male sex, former smoking, current smoking, diabetes, 
hypertension and a higher level of systolic blood pressure (SBP) and a lower level of high-
density lipoprotein (HDL). The individual articles that contributed to those meta-analyses 
are listed in the appendix (pp 29–45). 
The numbers of people affected by elevated cIMT and CP in the six WHO regions in 2015 
were generated based on a “risk factor model” by taking into account the regional 
difference in the exposure to three major risk factors, namely current smoking, diabetes 
and hypertension (appendix, p 1). As shown in Figure 3 and detailed in the appendix (p 
46), WPR had the largest share of global cases of elevated cIMT (33·36%, 317·62 million 
[95% CI=194·71-473·73]) and CP cases (33·20%, 240·77 million [95% CI=150·96-
359·22]). AFR had the least cases of elevated cIMT (6·21%, 59·08 million [95% CI=34·91-
92·19]) whereas EMR had the smallest share of CP cases (6·15%, 44·59 million [95% 
CI=27·36-68·44]). The age groups that contributed the most cases of elevated cIMT and 
CP were 50-59 years for AFR, SEAR and EMR, and 60-69 years for AMR, EUR and WPR. 
Discussion 
This systematic review and meta-analysis comprehensively portrays the prevalence of 
elevated cIMT, CP and CS in the general population worldwide. We found that more than 
one in four individuals aged 30-79 years had an abnormal cIMT of 1·0 mm and above, 
translating to more than one billion affected people in 2020. In addition, more than one 
in five people aged 30-79 years had CP and 1·50% were affected by CS, equivalent to 816 
million and 58 million cases in 2020. cIMT, CP and CS were more common in older than 
in younger people, and in males than in females. Current smoking, diabetes, and 
hypertension were confirmed as common risk factors for both elevated cIMT and CP. At 
the regional level, WPR had around one-third of global cases of elevated cIMT and CP, 
whereas AFR had the least cases of elevated cIMT and EMR had the least CP cases in 2015, 
demonstrating substantial variations across the globe. 
As revealed in our meta-regression, elevated cIMT, CP and CS become more common in 
older people, which reinforces the concept that atherosclerosis is a chronic disease 
process of the artery which manifests more commonly as people age 7, 8. cIMT measures 
the structural changes in the carotid arterial walls, and an increased cIMT could be a 
marker of early-stage systemic atherosclerosis, as well as of smooth muscle hypertrophy 
or hyperplasia 9. In our study, we found that over one in four individuals aged 30-79 years 
had an elevated cIMT, defined as a cIMT ≥1·0 mm . Although a cIMT of 1·0 mm and greater 
is considered as abnormal, some elevated cIMT conditions are clinically benign and may 
not progress to cardiovascular events 9, 22, 23. The 2016 European Guidelines on 
cardiovascular disease prevention in clinical practice does not recommend the 
implementation of cIMT measurements in daily clinical practice and routinely in 
cardiovascular risk assessment 9. The over one billion cases of elevated cIMT worldwide 
should not create unnecessary anxiety among stakeholders. Other advanced-stage 
phenotypes of carotid atherosclerosis, namely CP or CS, are correlated to elevated cIMT 
but reflect different predictive value for CVDs 24-26. Previous studies have suggested that 
people with CP or CS are at a higher risk of developing CVDs 10, 24, 27. The systematic 
detection of CP has been recommended in assessing cardiovascular risk 9. Given the fact 
that atherosclerosis is a diffuse disease of arteries, people with carotid atherosclerosis are 
more likely to have atherosclerotic diseases in other arterial beds, such as peripheral 
artery disease and coronary heart disease 28, 29. The large numbers of people living with 
CP and CS represent sizeable potential cardiovascular events and therefore a huge burden 
of diseases on the global health-care system 10, 27.  
In line with the meta-analysis by de Weerd and colleagues and previous investigations, 
our analysis also noted a clear male predominance in carotid atherosclerosis 12, 13, 30, 31. 
This widely accepted cardiovascular advantage in females might be conferred by the 
protective role of, for example, oestrogens in endothelial function and lipid homeostasis 
32-34. Smoking, diabetes and hypertension were revealed as significant factors for elevated 
cIMT and CP in our meta-analyses for risk factors, which agrees with previous 
epidemiological investigations 35-37. Early detection and management of diabetes and 
hypertension might help to slow the progression of atherosclerotic complications and 
much attention should be paid to subpopulations that are especially vulnerable, such as 
males, heavy smokers, people with established CVDs 9. For CP, we were able to identify 
the effects of both current smoking and former smoking, with the latter having a lower 
meta-OR. The difference between those two effects implies the potential benefits of 
smoking cessation in reducing the risk of CP 37, 38. For CP, a lower level of HDL was found 
to be a significant risk factor, which agrees with previous evidence as revealed in a 
systematic review 39. However, the association between elevated cIMT and the level of 
HDL was not assessed due to lack of relevant data, as was also the case with different 
lipids on elevated cIMT, CP and CS. More studies are still needed on the relationship 
between lipid profile and carotid atherosclerosis. 
To the best of our knowledge, this study is the first to derive robust prevalence estimates 
of carotid atherosclerosis in the general population at both the global and regional levels, 
serving to inform policymakers of the epidemiological magnitude and profile of this 
public health issue. A special merit of this study is the that we adopted the standardized 
definitions of carotid atherosclerosis, including elevated cIMT, CP and CS, before pooling 
prevalence estimates from different studies, which reduced the uncertainty of our 
estimation due to differing case definitions 9. Benefitting from a comprehensive search 
strategy and dual review process, we finally included a total of 59 articles for our 
modelling analysis. Sufficient data from the included articles enabled us to provide the 
broadest research scope of the epidemiological distribution of elevated cIMT, CP and CS 
simultaneously. We successfully provided prevalence estimates of elevated cIMT, CP and 
CS by age and sex. In the effect assessments of potential risk factors, only factors that were 
reported based on multivariable logistic regressions were included. This strict inclusion 
criterion could help to avoid the suspected bias caused by univariable logistic regression 
21. 
Our study has unavoidable limitations. The first crucial limitation is the deficiency of 
information on risk factors. For elevated cIMT, we were only able to explore the effects of 
seven potential risk factors and for CP only nine. The limited amount of information on 
risk factors for CS restricted our ability to conduct the risk factor assessment in a meta-
analytic manner. Furthermore, the effects of many important risk factors or covariates of 
elevated cIMT, CP and CS, such as hypercholesterolemia, obesity and physical exercise 
were not able to be established. A second limitation was that in the distribution of regional 
cases, only demographic structures (age and sex) and the exposure levels of three risk 
factors (current smoking, diabetes and hypertension) in different geographic regions 
were accounted for based on a “risk factor-based model”. Previous studies have suggested 
that the prevalence of carotid atherosclerosis might be lower in Asians compared to their 
Western counterparts; however, we were not able to assess the possible ethnic disparity 
due to the limited availability of relevant information 30, 40. The effects of ethnicity, 
together with other potential drivers of disease, were not able to be taken into account in 
our modelling at the regional level, which might have resulted in partially biased 
prevalence for each geographic region. In addition, the lack of risk factor assessment for 
CS restricted our ability to estimate the regional prevalence of CS. Thirdly, none of the 
included articles was based on investigations in EMR, so that our prevalence estimates for 
EMR might not precisely reflect the real situation. To better explore the distributions of 
diseases at finer dimensions, the need to scale up high-quality data on the epidemiology 
of carotid atherosclerosis, especially through prospective cross-national, studies using 
comparable definitions and assessments, is highlighted.  
To conclude, this study demonstrates that elevated cIMT and CP are common disorders 
in the general population. The large number of people living with CP and CS may bring a 
considerable burden of CVDs and represents a major public health concern worldwide. 
Smoking, diabetes and hypertension are common risk factors for both elevated cIMT and 
CP. Around one-third of global cases of elevated cIMT and CP were in WPR in 2015. Given 
the prominent role of ageing as a risk factor for carotid atherosclerosis, a larger number 
of people affected by carotid atherosclerosis are expected in the context of global 
demographic ageing.  
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Tables and Figures 
Table 1. Estimated prevalence of elevated cIMT, CP and CS in people aged 30-79 
years, by age group and sex 
Age group 
Elevated cIMT (%, 95% CI) CP (%, 95% CI) CS (%, 95% CI) 
Male Female Male Female Male Female 
30-34 years 
11·71 6·87 7·48 4·10 0·52 0·31 
(5·96-21·74) (3·40-13·38) (4·04-13·45) (2·18-7·60) (0·28-0·96) (0·17-0·57) 
35-39 years 
15·80 9·45 10·47 5·83 0·70 0·42 
(8·25-28·12) (4·76-17·87) (5·74-18·34) (3·12-10·62) (0·41-1·20) (0·25-0·72) 
40-44 years 
20·97 12·86 14·47 8·22 0·94 0·56 
(11·32-35·55) (6·63-23·47) (8·10-24·50) (4·46-14·66) (0·58-1·50) (0·35-0·89) 
45-49 years 
27·29 17·27 19·66 11·46 1·25 0·75 
(15·33-43·77) (9·14-30·21) (11·32-31·93) (6·33-19·89) (0·84-1·88) (0·50-1·12) 
50-54 years 
34·68 22·79 26·14 15·77 1·68 1·01 
(20·41-52·37) (12·48-37·94) (15·59-40·41) (8·90-26·41) (1·19-2·37) (0·72-1·42) 
55-59 years 
42·89 29·46 33·85 21·31 2·24 1·35 
(26·64-60·85) (16·79-46·35) (21·08-49·51) (12·39-34·16) (1·66-3·01) (1·00-1·81) 
60-64 years 
51·52 37·13 42·54 28·15 2·98 1·80 
(33·93-68·74) (22·21-55·00) (27·87-58·65) (16·98-42·87) (2·29-3·88) (1·38-2·35) 
65-69 years 
60·05 45·52 51·71 36·17 3·97 2·41 
(42·05-75·69) (28·74-63·38) (35·85-67·23) (22·82-52·05) (3·07-5·10) (1·86-3·11) 
70-74 years 
68·01 54·17 60·76 45·04 5·25 3·21 
(50·60-81·52) (36·28-71·04) (44·69-74·80) (29·95-61·10) (4·03-6·83) (2·44-4·20) 
75-79 years 
75·05 62·57 69·13 54·24 6·93 4·26 
(59·10-86·22) (44·54-77·68) (53·87-81·12) (38·20-69·45) (5·15-9·26) (3·13-5·77) 
Overall (30-79 
years) in 2020 
32·12 23·18 25·18 17·12 1·83 1·17 
(20·17-46·72) (13·71-35·93) (16·13-36·69) (10·39-26·46) (1·31-2·57) (0·84-1·63) 
Note: cIMT=carotid intima-media thickness; CP=carotid plaque; CS=carotid stenosis; CI=confidence 
interval. 
Table 2. Estimated number of people with elevated cIMT, CP and CS worldwide from 2000 to 2020 and the rates of change 
Age group 
Elevated cIMT (million, 95% CI) CP (million, 95% CI) CS (million, 95% CI) 
Relative rate of change 
(%, 2000-2020) 
2000 2020 2000 2020 2000 2020 CAS CP CS 
30-34 years 
44·56 56·56 27·80 35·30 2·00 2·54 
26·93 26·96 26·92 
(22·45-84·20) (28·50-106·86) (14·92-50·50) (18·94-64·11) (1·08-3·68) (1·38-4·68) 
35-39 years 
54·21 69·02 35·02 44·59 2·40 3·06 
27·32 27·33 27·32 
(27·96-98·73) (35·60-125·70) (19·05-62·20) (24·25-79·20) (1·40-4·11) (1·78-5·24) 
40-44 years 
63·38 83·73 42·52 56·17 2·81 3·71 
32·10 32·10 32·10 
(33·64-110·54) (44·44-146·03) (23·55-73·37) (31·11-96·92) (1·76-4·48) (2·32-5·92) 
45-49 years 
75·02 106·96 52·40 74·72 3·38 4·82 
42·59 42·59 42·59 
(41·21-124·50) (58·76-177·52) (29·71-87·23) (42·37-124·38) (2·26-5·05) (3·22-7·20) 
50-54 years 
76·03 128·08 55·43 93·39 3·55 5·98 
68·46 68·48 68·49 
(43·50-119·47) (73·30-201·23) (32·38-88·38) (54·57-148·89) (2·51-5·01) (4·24-8·44) 
55-59 years 
75·63 140·08 57·64 106·77 3·75 6·94 
85·21 85·23 85·24 
(45·38-112·12) (84·06-207·63) (34·96-87·47) (64·76-162·00) (2·78-5·04) (5·16-9·33) 
60-64 years 
83·24 142·23 66·30 113·29 4·48 7·67 
70·86 70·89 70·92 
(52·64-116·37) (89·96-198·78) (42·02-95·35) (71·81-162·91) (3·44-5·84) (5·88-9·98) 
65-69 years 
80·29 141·47 66·69 117·56 4·82 8·50 
76·21 76·27 76·39 
(53·69-106·05) (94·66-186·78) (44·42-90·77) (78·33-159·93) (3·73-6·21) (6·58-10·95) 
70-74 years 
71·58 114·27 61·77 98·69 4·89 7·83 
59·64 59·77 60·11 
(50·64-89·78) (80·94-143·18) (43·36-79·72) (69·36-127·23) (3·74-6·38) (5·99-10·22) 
75-79 years 
53·37 84·28 47·60 75·29 4·23 6·73 
57·92 58·20 59·31 
(39·84-63·99) (63·10-100·83) (35·21-58·52) (55·87-92·35) (3·13-5·68) (4·98-9·05) 
Overall (30-
79 years) 
677·32 1066·70 513·16 815·76 36·32 57·79 
57·49 58·97 59·13 
(410·96-1025·74) (653·30-1594·52) (319·58-773·52) (511·36-1217·93) (25·83-51·50) (41·52-81·02) 
Note: cIMT=carotid intima-media thickness; CP=carotid plaque; CS=carotid stenosis; CI=confidence interval.
Table 3. Synthesized effect size of risk factors for elevated cIMT and CP that were 
investigated in at least three studies using multivariate design 
Risk factor Number of studies OR (95% CI) z value P value 
Elevated cIMT 
Risk factor 1-Age (per 10-year increase) 4 2·71 (2·07-3·55) 7·26 <0·001 
Risk factor 2-Female sex 5 0·49 (0·38-0·64) 5·43 <0·001 
Risk factor 3-Current smoker 5 1·76 (1·34-2·30) 4·11 <0·001 
Risk factor 4-Current alcohol drinker 3 0·94 (0·70-1·26) 0·41 0·680 
Risk factor 5-Diabetes 4 2·23 (1·48-3·36) 3·82 <0·001 
Risk factor 6-Hypertension 5 1·55 (1·03-2·34) 2·08 0·038 
Risk factor 7-Dyslipidemia 3 0·90 (0·65-1·25) 0·61 0·542 
CP 
Risk factor 1-Age (per 10-year increase) 4 1·79 (0·93-3·43) 1·76 0·079 
Risk factor 2-Female sex 5 0·55 (0·33-0·94) 2·20 0·028 
Risk factor 3-Former smoker 3 1·58 (1·06-2·36) 2·26 0·024 
Risk factor 4-Current smoker 5 1·70 (1·41-2·04) 5·64 <0·001 
Risk factor 5-Diabetes 3 1·45 (1·12-1·90) 2·77 0·006 
Risk factor 6-Hypertension 3 1·75 (1·44-2·13) 5·56 <0·001 
Risk factor 7-SBP (per 10 mmHg increase) 3 1·11 (1·08-1·15) 6·50 <0·001 
Risk factor 8-HDL (per mmol/L increase) 3 0·46 (0·21-0·99) 1·98 0·048 
Risk factor 9-BMI (per kg/m2 increase) 4 0·97 (0·91-1·02) 1·15 0·249 
Note: cIMT=carotid intima-media thickness; CP=carotid plaque; OR=odds ratio; CI=confidence 
interval; SBP= Systolic Blood Pressure; HDL=high-density lipoprotein; BMI=body mass index; The 
definitions of some risk factors varied slightly across studies. ORs for binary variable risk factor 
indicated the risk of elevated cIMT/CP compared with those without the risk factor, except for current 




Figure 1. PRISMA diagram of study selection 
Note: cIMT=carotid intima-media thickness; CP=carotid plaque; CS=carotid stenosis. 
  
 
Figure 2. Age-and sex-specific prevalence of elevated cIMT, CP and CS, with 95% CI 
Note: CI, confidence interval; cIMT=carotid intima-media thickness; CP=carotid plaque; CS=carotid 
stenosis; For elevated cIMT and CS, the regression lines at younger (<40 years) and older (>75 years) 
age groups are based on few data points or projection only; For CS, to make the plot readable, the 
study by Savji N, et al.(2013) was removed when drawing the plot due to its overwhelmingly large 
sample size influence. 
  
 
Figure 3. Regional number of people with elevated cIMT and CP and contributing 
age groups in 2015 
Note: cIMT=carotid intima-media thickness; CP=carotid plaque; AFR= African Region; AMR= Region 
of the Americas; SEAR= South-East Asia Region; EUR= European Region; EMR= Eastern 
Mediterranean Region; WPR= Western Pacific Region; People with elevated cIMT and CP were 
restricted to those aged 30-79 years given the study context. 
